VYNE vs. VRCA, KRON, HOWL, IFRX, DTIL, GANX, CUE, TELO, AADI, and CNTX
Should you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Verrica Pharmaceuticals (VRCA), Kronos Bio (KRON), Werewolf Therapeutics (HOWL), InflaRx (IFRX), Precision BioSciences (DTIL), Gain Therapeutics (GANX), Cue Biopharma (CUE), Telomir Pharmaceuticals (TELO), Aadi Bioscience (AADI), and Context Therapeutics (CNTX). These companies are all part of the "pharmaceutical products" industry.
VYNE Therapeutics vs. Its Competitors
Verrica Pharmaceuticals (NASDAQ:VRCA) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.
In the previous week, VYNE Therapeutics had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 2 mentions for VYNE Therapeutics and 1 mentions for Verrica Pharmaceuticals. VYNE Therapeutics' average media sentiment score of 1.29 beat Verrica Pharmaceuticals' score of 0.94 indicating that VYNE Therapeutics is being referred to more favorably in the news media.
42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
VYNE Therapeutics has lower revenue, but higher earnings than Verrica Pharmaceuticals. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Verrica Pharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500.
Verrica Pharmaceuticals presently has a consensus price target of $8.00, suggesting a potential upside of 1,134.00%. VYNE Therapeutics has a consensus price target of $6.25, suggesting a potential upside of 313.91%. Given Verrica Pharmaceuticals' higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than VYNE Therapeutics.
Verrica Pharmaceuticals has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,974.55%. Verrica Pharmaceuticals' return on equity of 0.00% beat VYNE Therapeutics' return on equity.
Summary
VYNE Therapeutics beats Verrica Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get VYNE Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VYNE Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VYNE) was last updated on 7/3/2025 by MarketBeat.com Staff
